DEXCOM INC

Insider sales: EVP Michael Brown’s July 15th Dexcom share sale shows disciplined 10‑b5‑1 trading, not distress, but signals investors to watch market sentiment and portfolio shifts.

Dexcom insider sale: EVP Brown sells 1,700 shares at $75.55—routine transaction, no short‑term impact, focus on product pipeline & growth.

Insider selling at Dexcom: EVP Michael Jon Brown’s May 2026 sale signals caution amid a 52‑week high, market volatility, and upcoming Dexcom Flex launch.

Dexcom insider Collins Richard Alexander sold and rebought 5,074 shares under a trust, keeping 40,162 shares to safeguard assets while staying committed to the company’s long‑term growth.

Insider sale of 1,700 Dexcom shares by EVP Michael Jon Brown shows disciplined liquidity management—not a bearish signal; focus remains on product growth and buyback plans.

Dexcom insider sale: EVP Michael Brown sells 1,700 shares under 10(b)(5)(1) – a routine liquidity move that shouldn’t affect the stock’s growth outlook.

Dexcom insider activity: CFO’s RSU grant signals confidence in CGM growth and may temper recent price dips.